KIR, HLA - C, & Rituximab
Feb 10, 2022•22 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This week we hype the seemingly negative impact of KIR2DS1/HLA-C2/C2 genotype on rituximab benefit in aggressive lymphomas.
We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab).
KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0
Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651
Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis: https://doi.org/10.1016/S1470-2045(21)00758-0
Cemiplimab in cervical cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2112187
For the best experience, listen in Metacast app for iOS or Android